TPST: tempesttx.com Company Total Sales

tempesttx.com - graphic logo of issuer TPST

The trading revenue trend of Tempest Therapeutics (TPST) correlates with the environmental compliance of external partner contractors, with the current metric equal to 0.00. The business relies on a high scientific reputation for creating targeted molecules. Operational efficiency is increasing through the application of AI in compound modeling and synthesis automation, although final tests remain the responsibility of physicians.

TPST Tempest Therapeutics: Company Revenue in the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Tempest Therapeutics, Inc. (TPST)

- market price and analyst price targets:
Comprehensive company analysis:Tempest Therapeutics
Manufactured products of Tempest Therapeutics

The development of innovative immuno-oncology drugs by Tempest Therapeutics (TPST) requires precise control of incoming cash flows. This metric aggregates the daily volume of actual receipts, transforming operational activity into a quantitative cash equivalent. High inflow intensity confirms commercial demand and shortens the path to achieving positive free cash flow. Analyzing the company's sales financial indicator allows investors to assess the real-time execution speed of the business plan.

Competing companies

Company Total Revenue BeiGene Oncology ONC|Company Sales HALO (Halozyme Therapeutics)|Company Total Sales RVMD|Revenue and Sales Volume AAPG (Ascentage Pharma)|CG Oncology Inc (CGON) - Company Total Revenue|URGN - Company Revenue|Bicara Corp (BCAX) - Company Sales|Personalis, Inc. (PSNL) - Company Revenue|Company Annual Revenue ERAS (erasca.com)|DCTH (Delcath Systems) - Revenue and Sales Volume|Company Total Revenue Y-mAbs Therapeutics Inc YMAB|Company Revenue Aura Bio (AURA)|Company Gross Revenue candeltx.com|Accuray Incorporated - Company Sales|Company Total Sales SLS (SELLAS Life Sciences Group, Inc.)|ACTU: Company Sales|Company Sales Revenue CTOR (Citius Oncology Inc.)|HURA (tuhurabio.com) - Company Sales|TARA: Company Total Sales|FATE (Fate Therapeutics, Inc.) - Revenue and Sales Volume|WHWK: Company Sales Revenue|Revenue and Sales Volume TCRX|CSBR - Company Total Revenue|Company Revenue XBiotech XBIT|Company Sales Revenue CVM|OS Therapies Incorporated - Revenue and Sales Volume|RADX - Revenue and Sales Volume|artivabio.com (ARTV) - Company Revenue|Company Annual Revenue ANL (Adlai Nortye)|VERU (Veru Pharma) - Revenue and Sales Volume|Company Total Revenue Xilio XLO|Company Sales RENB (Renovaro Inc.)|Revenue and Sales Volume muraloncology.com (MURA)|Kairos Pharma - Company Sales|Company Total Sales OKUR (OnKure Therapeutics, Inc.)|CytoMed - Revenue and Sales Volume|Company Gross Revenue Curis, Inc. CRIS|APLM: Revenue and Sales Volume|Company Sales tharimmune.com|Company Revenue Advanced Biomed Inc.|Genprex Inc. (GNPX) - Company Gross Revenue|Company Sales CLDI (Calidi Biotherapeutics)|Company Total Sales SBFM|Company Revenue Xenetic Biosciences, Inc. XBIO|SLRX (salariuspharma.com) - Company Annual Revenue|PPBT - Company Revenue|Company Gross Revenue American Oncology Network AONC|BGNE (BeOne Medicines) - Company Sales|CKPT: Company Total Sales|ELEV (Elevation Oncology, Inc.) - Revenue and Sales Volume|Company Sales iCAD Corp (ICAD)|Revenue and Sales Volume IKNA|Revenue and Sales Volume Notable Labs Ltd (NTBL)|Company Revenue Viracta Therapeutics, Inc. VIRX|MOR: Company Sales Volume|NAYA Biosciences - Revenue and Sales Volume|ascentage.com (AAPGV) - Company Sales